Dr. Michael Singel is a pharmacist who is specialized in Oncology in Baltimore, Maryland. Patients can reach him at 401 N Broadway St Rm 1370, Baltimore or contact him on 443-927-0443. Active license number of Dr. Michael Singel is 25949 for Oncology in Maryland. Dr. Michael Singel is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Dr. Michael Singel speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. Michael Singel
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Male
Location:
401 N Broadway St Rm 1370, Baltimore, Maryland, 21287-0019
Phone:
443-927-0443
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Michael Singel are as mentioned below.
NPI Number:
1144042763
NPI Enumeration Date:
25 Oct, 2024
NPI Last Update On:
25 Oct, 2024
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Michael Singel are as mentioned below.
Specialization
License Number
State
Status
Oncology
25949
Maryland
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1008 N Durham St, Baltimore, Maryland
Zip:
21205-1468
Phone Number:
724-799-3052
Fax Number:
--
Patients can reach Dr. Michael Singel at 401 N Broadway St Rm 1370, Baltimore, Maryland or can call on phone at 443-927-0443.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.